London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company X-Chem, regarding the acquisitions of Glamorous AI and ComInnex.
X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognised leader in generating actionable results to drive small molecule drug discovery, announced that it has acquired Glamorous AI, a leader in Artificial Intelligence (AI) solutions for drug discovery and ComInnex, a European leader in chemistry services supporting early-stage drug discovery.
Glamorous AI is the leading AI solution for the entire drug discovery process, merging high-quality, large DEL datasets with medicinal chemistry data to enable the rapid identification of starting points for drug discovery, yielding a higher probability of success from screening to clinical candidate through accelerated outcomes. The acquisition positions X-Chem as a leading service provider in machine learning-driven drug discovery. “What AlphaFold did for protein folding, X-Chem and Glamorous AI will do for drug discovery” said Matt Clark, Ph.D., CEO of X-Chem. “Glamorous AI brings cutting-edge solutions to the entire small molecule drug discovery process. By combining the data-generating power of our leading DEL platform with Glamorous’ AI capability, we will accelerate our partners’ drug discovery programs and get medicines to patients faster.”
Based in Hungary, ComInnex has deep expertise in synthetic chemistry services and novel chemical technologies, supporting early-stage drug discovery. With demand for high-quality discovery services increasing across the world, this complementary pairing of X-Chem, a North American leader in DEL and medicinal chemistry with ComInnex, a European leader in synthetic chemistry and custom DEL services delivers the capacity, geographic footprint and expertise to better serve the demands of customers in a global market. “As a united company, with an increased global presence, we are positioned to meet the increasing demand for innovative chemistry solutions and high-quality discovery services worldwide,” noted Matt Clark, Ph.D., CEO of X-Chem. “The acquisition of ComInnex further extends X-Chem’s expertise and scale of DEL services to help biopharma clients of any size efficiently unlock exponential possibilities in small molecule drug discovery.”
– Ends –
GHO Capital Partners LLP
T +44 20 3700 7440
About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.
X-Chem, Inc. is a leader in small molecule discovery science, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimisation. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. X-Chem empowers partners to rapidly screen billions of diverse, drug-like compounds simultaneously and easily identify potent hits that exhibit desired selectivity and mode of action with attractive physicochemical properties. In-house lead optimisation services enable clients to progress their compounds directly for even higher quality outputs. Our expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery, supporting lead optimisation through candidate identification. For more information, please visit www.x-chemrx.com.
About Glamorous AI
Glamorous AI is radically changing how drugs are designed and optimised using our proprietary artificial intelligence platform, RosalindAI. RosalindAI specialises in solving challenges inherent to sparse and noisy data sets that makes the majority of disease-associated targets intractable by existing computational technologies. By building transformative AI solutions and integration with biology and chemistry, we empower organisations to discover new drugs and deliver the right drug to the right patient. For more information, please visit www.glamorous.ai.
ComInnex is a synthetic chemistry group passionate about small molecule design and synthesis. Based in Budapest, Hungary, ComInnex supports early-stage drug discovery through a range of products and services, focusing on the latest technologies and adapting to new and emerging trends. The ComInnex platform and toolkit enables rapid design and validation of novel E3 ligase ligands and linkers for targeted protein degradation to accelerate research projects in this area. For more information, please visit https://cominnex.com/.